CN113845424A - Right camphol ester compound and pharmaceutical application thereof - Google Patents
Right camphol ester compound and pharmaceutical application thereof Download PDFInfo
- Publication number
- CN113845424A CN113845424A CN202111199113.5A CN202111199113A CN113845424A CN 113845424 A CN113845424 A CN 113845424A CN 202111199113 A CN202111199113 A CN 202111199113A CN 113845424 A CN113845424 A CN 113845424A
- Authority
- CN
- China
- Prior art keywords
- target compound
- compound
- ester compound
- camphanol
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 camphol ester compound Chemical class 0.000 title claims abstract description 11
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 title description 8
- 239000003814 drug Substances 0.000 claims abstract description 12
- 230000006378 damage Effects 0.000 claims abstract description 10
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 4
- 125000004122 cyclic group Chemical group 0.000 claims abstract description 3
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 48
- 208000006011 Stroke Diseases 0.000 claims description 9
- 208000027418 Wounds and injury Diseases 0.000 claims description 8
- 208000014674 injury Diseases 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 3
- 241000843353 Embelia Species 0.000 claims 1
- 150000004492 retinoid derivatives Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 206010008118 cerebral infarction Diseases 0.000 description 17
- 229940125904 compound 1 Drugs 0.000 description 17
- 102000027484 GABAA receptors Human genes 0.000 description 15
- 108091008681 GABAA receptors Proteins 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 229940125782 compound 2 Drugs 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 229940126214 compound 3 Drugs 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 230000007971 neurological deficit Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 201000006474 Brain Ischemia Diseases 0.000 description 8
- 206010008120 Cerebral ischaemia Diseases 0.000 description 8
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 229940125898 compound 5 Drugs 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 208000026106 cerebrovascular disease Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 5
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 5
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 5
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 4
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000010410 reperfusion Effects 0.000 description 4
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229940116229 borneol Drugs 0.000 description 3
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 3
- 210000001168 carotid artery common Anatomy 0.000 description 3
- 210000000269 carotid artery external Anatomy 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000004576 sand Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 210000004004 carotid artery internal Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000003657 middle cerebral artery Anatomy 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- WGKORGIPQUAKOI-UHFFFAOYSA-N 3-cyclopropyloxy-3-oxopropanoic acid Chemical compound OC(=O)CC(=O)OC1CC1 WGKORGIPQUAKOI-UHFFFAOYSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- NKKMPIXWEPUSCG-UHFFFAOYSA-N 5-oxooctanal Chemical compound CCCC(=O)CCCC=O NKKMPIXWEPUSCG-UHFFFAOYSA-N 0.000 description 1
- 206010008092 Cerebral artery thrombosis Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- HGINADPHJQTSKN-UHFFFAOYSA-N Monoethyl malonic acid Chemical compound CCOC(=O)CC(O)=O HGINADPHJQTSKN-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- KJOZJSGOIJQCGA-UHFFFAOYSA-N dichloromethane;2,2,2-trifluoroacetic acid Chemical compound ClCCl.OC(=O)C(F)(F)F KJOZJSGOIJQCGA-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical group O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- PHXULIQFYALWBW-UHFFFAOYSA-N propanedioic acid propane-1,2,3-triol Chemical compound C(CC(=O)O)(=O)O.OCC(O)CO PHXULIQFYALWBW-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
- C07C69/38—Malonic acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/06—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton from hydroxy amines by reactions involving the etherification or esterification of hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
- C07C227/20—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters by hydrolysis of N-acylated amino-acids or derivatives thereof, e.g. hydrolysis of carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/03—Preparation of carboxylic acid esters by reacting an ester group with a hydroxy group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/08—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C69/743—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring of acids with a three-membered ring and with unsaturation outside the ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Emax | EC50 | Emax | EC50 | |||
Object Compound 1 | 108.6±21.8 | 1.46±0.003 | Target Compound 7 | / | / | |
Target Compound 2 | / | / | Target Compound 8 | / | / | |
Target Compound 3 | / | / | Target Compound 9 | 107.5±20.7 | 1.39±0.003 | |
Target Compound 4 | / | / | Control Compound 1 | / | / | |
Target Compound 5 | / | / | Control Compound 2 | / | / | |
Target Compound 6 | 106.6±22.3 | 1.44±0.003 | Control Compound 3 | / | / |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111199113.5A CN113845424B (en) | 2021-10-14 | 2021-10-14 | Right-embedding alcohol ester compound and its pharmaceutical use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111199113.5A CN113845424B (en) | 2021-10-14 | 2021-10-14 | Right-embedding alcohol ester compound and its pharmaceutical use |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113845424A true CN113845424A (en) | 2021-12-28 |
CN113845424B CN113845424B (en) | 2023-09-12 |
Family
ID=78978401
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111199113.5A Active CN113845424B (en) | 2021-10-14 | 2021-10-14 | Right-embedding alcohol ester compound and its pharmaceutical use |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113845424B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023065071A1 (en) * | 2021-10-18 | 2023-04-27 | 苏州沪云新药研发股份有限公司 | Use of borneol in preparation of drug for treating cerebral ischemic stroke |
CN116407529A (en) * | 2023-03-24 | 2023-07-11 | 南京医科大学 | Pharmaceutical use of esters of 3-nitro-2, 6-dihydroxybenzoic acid right-hand or fenchyl alcohol |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19509697A1 (en) * | 1995-03-08 | 1996-09-12 | Schering Ag | New borneol ester of 3-amino-2-hydroxy-3-phenyl-propionic acid or deriv. |
CN1537843A (en) * | 2003-04-15 | 2004-10-20 | ������˹��ѧƷŷ������˾ | Carboxylic acid esters on basis of 2-hydroxy-methyl-norbornane |
US20100179097A1 (en) * | 2004-05-19 | 2010-07-15 | Wen Tan | Use of kauranes compounds in the manufacture of medicament |
CN102180832A (en) * | 2011-03-18 | 2011-09-14 | 苏州沪云肿瘤研究中心有限公司 | Compound for protecting cerebral ischemia and preparation method thereof |
US20180009859A1 (en) * | 2015-01-15 | 2018-01-11 | The Johns Hopkins University | Pharmacological modulators of gabaa receptors and their use |
CN108047048A (en) * | 2017-12-30 | 2018-05-18 | 苏州沪云肿瘤研究中心股份有限公司 | A kind of benzenpropanoic acid ester type compound and its preparation method and application |
US20180141895A1 (en) * | 2015-01-13 | 2018-05-24 | Xi'an Libang Pharmaceutical Co., Ltd | Diphenyl derivative and uses thereof |
CN108084030A (en) * | 2017-12-30 | 2018-05-29 | 苏州沪云肿瘤研究中心股份有限公司 | A kind of cinnamic acid esters compound and its preparation method and application |
CN109608356A (en) * | 2018-12-14 | 2019-04-12 | 南京医科大学 | The derivative of acylated amino acid (+) the 2- down alcohol ester of a kind of malonic acid monoester and its application |
CN111302959A (en) * | 2020-02-28 | 2020-06-19 | 宁波南大光电材料有限公司 | Acid diffusion inhibitor with ester bond, preparation method thereof and photoresist composition |
CN112592470A (en) * | 2020-12-10 | 2021-04-02 | 万华化学集团股份有限公司 | Antibacterial polyester polyol, preparation method thereof and antibacterial polyurethane |
-
2021
- 2021-10-14 CN CN202111199113.5A patent/CN113845424B/en active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19509697A1 (en) * | 1995-03-08 | 1996-09-12 | Schering Ag | New borneol ester of 3-amino-2-hydroxy-3-phenyl-propionic acid or deriv. |
CN1537843A (en) * | 2003-04-15 | 2004-10-20 | ������˹��ѧƷŷ������˾ | Carboxylic acid esters on basis of 2-hydroxy-methyl-norbornane |
US20100179097A1 (en) * | 2004-05-19 | 2010-07-15 | Wen Tan | Use of kauranes compounds in the manufacture of medicament |
CN102180832A (en) * | 2011-03-18 | 2011-09-14 | 苏州沪云肿瘤研究中心有限公司 | Compound for protecting cerebral ischemia and preparation method thereof |
US20180141895A1 (en) * | 2015-01-13 | 2018-05-24 | Xi'an Libang Pharmaceutical Co., Ltd | Diphenyl derivative and uses thereof |
US20180009859A1 (en) * | 2015-01-15 | 2018-01-11 | The Johns Hopkins University | Pharmacological modulators of gabaa receptors and their use |
CN108047048A (en) * | 2017-12-30 | 2018-05-18 | 苏州沪云肿瘤研究中心股份有限公司 | A kind of benzenpropanoic acid ester type compound and its preparation method and application |
CN108084030A (en) * | 2017-12-30 | 2018-05-29 | 苏州沪云肿瘤研究中心股份有限公司 | A kind of cinnamic acid esters compound and its preparation method and application |
US20200331842A1 (en) * | 2017-12-30 | 2020-10-22 | Suzhou Pharmavan Co., Ltd | Phenylpropionate compound, preparation method for same, and applications thereof |
CN109608356A (en) * | 2018-12-14 | 2019-04-12 | 南京医科大学 | The derivative of acylated amino acid (+) the 2- down alcohol ester of a kind of malonic acid monoester and its application |
CN111302959A (en) * | 2020-02-28 | 2020-06-19 | 宁波南大光电材料有限公司 | Acid diffusion inhibitor with ester bond, preparation method thereof and photoresist composition |
CN112592470A (en) * | 2020-12-10 | 2021-04-02 | 万华化学集团股份有限公司 | Antibacterial polyester polyol, preparation method thereof and antibacterial polyurethane |
Non-Patent Citations (3)
Title |
---|
TAO WANG ET AL.: "A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia", 《ALZHEIMER\'S RESEARCH & THERAPY》, vol. 12, pages 1 - 10 * |
刘明等: "丹参素冰片醋对大脑中动脉栓塞大鼠的保护作用", 《中国药理学通报》, vol. 25, pages 301 - 303 * |
王涛等: "(+)-顺丁烯二酸单冰片酯与天然冰片镇痛作用的比较研究", 《中药药理与临床》, vol. 25, no. 2, pages 53 - 54 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023065071A1 (en) * | 2021-10-18 | 2023-04-27 | 苏州沪云新药研发股份有限公司 | Use of borneol in preparation of drug for treating cerebral ischemic stroke |
CN116407529A (en) * | 2023-03-24 | 2023-07-11 | 南京医科大学 | Pharmaceutical use of esters of 3-nitro-2, 6-dihydroxybenzoic acid right-hand or fenchyl alcohol |
CN116407529B (en) * | 2023-03-24 | 2024-05-10 | 南京医科大学 | Pharmaceutical use of esters of 3-nitro-2, 6-dihydroxybenzoic acid right-hand or fenchyl alcohol |
Also Published As
Publication number | Publication date |
---|---|
CN113845424B (en) | 2023-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2963057T3 (en) | Nicotinamide riboside crystalline form | |
CN113845424A (en) | Right camphol ester compound and pharmaceutical application thereof | |
JP2017128605A (en) | Solid forms of antiviral compound | |
CN101486744B (en) | Polyethyleneglycol modified scutellarin compound and preparation thereof | |
JP5841672B2 (en) | N-benzylaniline derivatives and uses thereof | |
KR101986272B1 (en) | Tricyclic compounds, compositions comprising them and uses thereof | |
CN104837810A (en) | Ketamine derivatives | |
CN103816152A (en) | Application and preparation method of berberine compound | |
CN114181087A (en) | 2, 6-dihydroxy benzoic acid right camphol ester compound and pharmaceutical application thereof | |
CN108715579B (en) | Organic amine ester derivative medicine of 2- (α hydroxypentyl) benzoic acid | |
US20160244421A1 (en) | Derivative of Butylphthalide and Preparation Method and Use Thereof | |
CN115991698B (en) | Heterocyclic compound and preparation method and application thereof | |
CN113559102B (en) | Compositions comprising a combination of a TRH analogue and propyloctanoic acid and pharmaceutically acceptable salts of propyloctanoic acid | |
CN115536607A (en) | Heteroatom-substituted aromatic compound and preparation method and application thereof | |
JP7498504B2 (en) | Use of aminothiol compounds as neuroprotective agents for the brain or heart | |
CN111233789B (en) | 2-piperazine ethyl phenyl carbamate derivatives and pharmaceutical application thereof | |
CN115245515A (en) | Medical application of composition | |
JP2019531353A (en) | Deuterated compounds and their pharmaceutical use | |
CN109608356B (en) | Malonic monoester acylated amino acid (+) 2-chamaenol ester derivatives and application thereof | |
CN104478798B (en) | N-aminoalkyl-3-pyridinecarboxamide derivative and application of N-aminoalkyl-3-pyridinecarboxamide derivative in preparation of drugs for treating cardiovascular and cerebrovascular diseases | |
CN108774254B (en) | 2, 6-diisopropylbenzene boric acid derivatives and pharmaceutical application thereof | |
CN109180712B (en) | 2-arrowhead alcohol arylboronic acid ester derivatives and application thereof | |
CN107722002B (en) | The twin medicine of 4-ASA derivative and Tubastatin A that a kind of N- benzyl replaces and its application | |
WO2020019994A1 (en) | Compound having neuroprotective effect, preparation method therefor and use thereof | |
JP2022508467A (en) | Cholinesterase inhibitor crystal polymorphs and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20211228 Assignee: Suzhou Nanyi University Innovation Center Assignor: NANJING MEDICAL University Contract record no.: X2024980005048 Denomination of invention: Right Kan alcohol ester compounds and their medicinal applications Granted publication date: 20230912 License type: Common License Record date: 20240429 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240906 Address after: Room 323, Building 3, No. 9 Suhong West Road, Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone, Suzhou City, Jiangsu Province 215124 Patentee after: Suzhou Yuanju Pharmaceutical Technology Co.,Ltd. Country or region after: China Address before: 211166 No. 101 Longmian Avenue, Jiangning District, Nanjing City, Jiangsu Province Patentee before: NANJING MEDICAL University Country or region before: China |